title: Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report.
authors.affiliation: Department of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, Tokyo, Japan.
authors.forename: Kazue
authors.initials: K
authors.lastname: Shiozawa
authors.forename: Manabu
authors.initials: M
authors.lastname: Watanabe
authors.forename: Hiroki
authors.initials: H
authors.lastname: Takenaka
authors.forename: Hidenari
authors.initials: H
authors.lastname: Nagai
authors.forename: Koji
authors.initials: K
authors.lastname: Ishii
authors.forename: Ken
authors.initials: K
authors.lastname: Sakai
authors.forename: Yasukiyo
authors.initials: Y
authors.lastname: Sumino
mesh_terms: D000142:Acidosis, Respiratory / Q000139:chemically induced; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005260:Female; D006801:Humans; D033461:Hyperuricemia / Q000139:chemically induced; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib; D014057:Tomography, X-Ray Computed; D015275:Tumor Lysis Syndrome / Q000209:etiology*
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib